The Morellato Group is the protagonist of a success story, and works alongside men and women who long ago adopted a responsible stance towards the environment and society. It applies the principles of the I.L.O. (International Labour Organization) strictly, to ensure the dignity and rights of all the workers involved in its production supply chain are safeguarded.
The diamonds used in its jewellery and watch collections are exclusively “No Blood” and with the introduction of those lab-grown, the diamond takes on an eco-friendly connotation for the Morellato Group. Every gemstone is mined and subsequently transformed with a mechanical process that respects the environment, calling for less energy and water than mined diamonds.
Conformity with environmental and health regulations is ensured for all materials used. Furthermore, thanks to the increasing use of recycled materials, leather and plastic, Morellato Group contributes to the reduction of the consumption of water, electricity and CO2 emissions in production processes.
Morellato Group embraces a 360 ° green vision. Between the end of 2019 and the beginning of 2020, the Group has gradually made its premises completely plastic-free, eliminating the vending machines of plastic bottles and introducing new vending machines for drinks, including organic ones, which are distributed in biodegradable or recyclable containers.
In the same time, corporate welfare is developed with more welcoming workplaces and premises allocated for socialising and relaxing. The Padua headquarters inaugurates new company premises designed to improve the quality of the working environment: a Kanteen (eating area) and a Relaxation Area.
A 10,000 sqm Park was also inaugurated, a private green lung alongside the company. Planted up with almost 400 trees and shrubs, the ground has a 1km walkway with benches and ping-pong tables.
For many years, the Morellato Group has actively played a part in major projects and social responsibility initiatives.
Together with the Association “Doctors with Africa” Cuamm (the most important Italian NGO operating in Africa), Morellato Group supports the important program "Mothers and Children first". The aim of the project is to ensure safe childbirth and nutritional interventions to support mothers and children in the first 1,000 days, that is, the time from the beginning of pregnancy to the two years of the baby's life.
Doctors with Africa CUAMM is present in 8 countries of sub-Saharan Africa (Angola, Ethiopia, Mozambique, Tanzania, Central African Republic, Sierra Leone, South Sudan and Uganda) and with the program "Mothers and Children First" wants to ensure assisted childbirth to 320,000 women and nutritional assistance to 60,000 children.
Morellato Group supported the program at Wolisso hospital in Ethiopia. With 200 beds, this hospital guarantees over 15,000 hospitalizations, 10,000 prenatal check-ups and 4,600 assisted births in one year. Over 1,200,000 people rely to this hospital and the network of 20 medical centres in the surrounding area. The hospital also runs a school for nurses and obstetricians, supplying qualified staff and training.
Since 2014 “Doctors with Africa” CUAMM has also been present at the Cueibet hospital in South Sudan, to which 178,000 people refer. Thanks to the support of Morellato Group, “Doctors with Africa” Cuamm has committed itself with the local government for the activities of strengthening the facilities, to offer the complete package of treatments in case of emergencies related to childbirth, for the health of mothers and children.
In Rumbek, also in South Sudan, Morellato's support made it possible to complete the renovation of the spaces and repair the hospital fence, to which over 545,000 people refer.
Morellato Group has also been a partner of the Cystic Fibrosis Charitable Research Foundation (FFC) founded in 1997 by Matteo Marzotto, a member of the Group’s Board. The Foundation supports important scientific research projects, the main aim of which is to help wipe out cystic fibrosis.
Since 2002 the Foundation has invested 28,000,000 Euro, funding 366 research projects geared towards improving the care currently available. In so doing it has increased the quality and length of the lives of patients, whilst also working on the root of the defect which causes cystic fibrosis with an end to finding a definitive cure.